Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAMUSCULAR, SUBCUTANEOUSGeneric

EVZIO

NALOXONE HYDROCHLORIDE

Standard Dose
0.4MG/0.4ML (0.4MG/0.4ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Summary

Approval overview EVZIO is listed in Drugs@FDA under application 205787 (NDA).

Review priority: PRIORITY Marketing status: Discontinued Active ingredient NALOXONE HYDROCHLORIDE Form and strength SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS - 0.4MG/0.4ML (0.4MG/0.4ML) Sponsor KALEO INC Submission history Latest submission status date: 2016-06-23 00:00:00.

Structured Monograph

Clinical summary

Approval overview EVZIO is listed in Drugs@FDA under application 205787 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient NALOXONE HYDROCHLORIDE Form and strength SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS - 0.4MG/0.4ML (0.4MG/0.4ML) Sponsor KALEO INC Submission history Latest submission status date: 2016-06-23 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.